Plain-English translation of NCT06959641 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called (XL092) as a first-line treatment for people with advanced thyroid cancer that has stopped responding to radioactive iodine. The study will enroll about 33 people and follow them for a year to see whether this medication can slow or stop their cancer from progressing. The goal is to understand if this treatment works, how well patients tolerate it, and how it affects their quality of life.
Radioactive iodine used to be a very effective treatment for differentiated thyroid cancer, but some people's cancers become resistant to it over time. When that happens, there are limited treatment options available. This trial exists to provide a new therapeutic choice for people whose cancer has become resistant to radioactive iodine and for whom standard treatments are no longer working.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once daily for 21 days, then have a 21-day break, and repeat this cycle as long as the treatment is working and you are tolerating it well. Throughout the study, you will have regular imaging scans (CT or MRI), blood and urine tests, and check-in visits with the research team. After you finish taking the medication, the team will follow up with you at 30 days, and then every 3 months for a year to monitor your health and how you are doing.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States